FDA
-
healthStanford’s James Zou on AI as Co-Scientist in Medicine
Stanford biomedical AI expert James Zou discusses autonomous AI agents, clinical trial inclusivity, FDA-cleared algorithms, real-world data challenges, and wearable-driven disease prediction.
-
healthLidl Recalls Chocolate Ladybugs Over Undeclared Hazelnut Allergen
Lidl US issues a nationwide recall of Favorina Chocolate Ladybugs due to undeclared hazelnuts, posing serious risks to those with tree nut allergies.
-
healthNew Study Links Wegovy to Nearly Fivefold Increase in Sudden Vision Loss Compared to Ozempic
Analysis of seven years of FDA data indicates Wegovy users face significantly higher risks of ischemic optic neuropathy compared to Ozempic patients.
-
healthFDA Rejects Autism Drug Claims, Approves Leucovorin for Rare Genetic Disorder
The FDA approved leucovorin for cerebral folate deficiency, contradicting previous Trump administration claims of its effectiveness for autism and finding insufficient evidence for broader use.
-
healthFDA Cracks Down on 30 Telehealth Firms Over Illegal GLP-1 Marketing
The FDA has issued warning letters to 30 telehealth companies for misleading marketing of GLP-1 products, including false claims and obscured sourcing.
-
healthFauci Commands Higher Trust Than Kennedy Jr. Among Americans
New survey reveals Americans place greater confidence in Dr. Anthony Fauci than in Health Secretary Robert F. Kennedy Jr., highlighting a trust divide in public health leadership.
-
healthSanofi Taps Belén Garijo: Pharma Regulatory Shifts and Nipah Virus Vaccine Advance
Sanofi appoints Belén Garijo as CEO, the FDA revises trial requirements, and progress accelerates on a Nipah virus vaccine, highlighting key pharma innovations in February 2026.
-
healthEli Lilly's Orforglipron Shows Promise in Weight Loss Drug Race
New clinical trial results suggest Eli Lilly's orforglipron may outperform oral semaglutide in glycemic control and weight reduction for type 2 diabetes.